Evaluation of flibanserin science and advocacy at the FDA

Walid F. Gellad; Kathryn E. Flynn; G. Caleb Alexander

doi:10.1001/jama.2015.8405

Evaluation of flibanserin science and advocacy at the FDA

Walid F. Gellad, Kathryn E. Flynn, G. Caleb Alexander

Bloomberg School of Public Health

Research output: Contribution to journal › Comment/debate › peer-review

32 Scopus citations

Original language	English (US)
Pages (from-to)	869-870
Number of pages	2
Journal	JAMA - Journal of the American Medical Association
Volume	314
Issue number	9
DOIs	https://doi.org/10.1001/jama.2015.8405
State	Published - Sep 1 2015

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jama.2015.8405

Cite this

@article{ec131201effc43c5aa8d8f9a0c28d424,

title = "Evaluation of flibanserin science and advocacy at the FDA",

author = "Gellad, {Walid F.} and Flynn, {Kathryn E.} and Alexander, {G. Caleb}",

year = "2015",

month = sep,

day = "1",

doi = "10.1001/jama.2015.8405",

language = "English (US)",

volume = "314",

pages = "869--870",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "9",

}

TY - JOUR

T1 - Evaluation of flibanserin science and advocacy at the FDA

AU - Gellad, Walid F.

AU - Flynn, Kathryn E.

AU - Alexander, G. Caleb

PY - 2015/9/1

Y1 - 2015/9/1

UR - http://www.scopus.com/inward/record.url?scp=84940749847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940749847&partnerID=8YFLogxK

U2 - 10.1001/jama.2015.8405

DO - 10.1001/jama.2015.8405

M3 - Comment/debate

C2 - 26148201

AN - SCOPUS:84940749847

SN - 0098-7484

VL - 314

SP - 869

EP - 870

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 9

ER -

Evaluation of flibanserin science and advocacy at the FDA

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this